Abstract\nBackground: Although some latest studies have shown that long non-coding RNA linc00312 may be markedly associated with solid tumors, the results remain not clear. Therefore, this study sought to evaluate the clinicopathological and diagnostic value of linc00312 for solid tumors. \nMethods: Differential gene expression of linc00312 between cancer and corresponding normal tissues were analyzed for ten common types of solid tumors in TCGA database. Receiver operating characteristic (ROC) curve was then employed using TCGA. We also conducted the online databases search for all eligible studies. A meta-analysis was performed using Stata 12.0 software. \nResults: Compared to corresponding normal tissues, linc00312 expression was significantly down-regulated in most types of solid tumors. Four published studies and two TCGA based diagnosis tests were included. The results of four published studies showed that down-regulation of linc00312 is positively associated with overall survival (HR=0.48, 95% CI: 0.21-0.75, P=0.001), tumor size (OR=4.45, 95% CI: 2.75-7.20, P=0.000), but not with lymph node metastasis (OR=1.23, 95% CI: 0.57-2.68, P=0.60). Our data showed that linc00312 expression profiling harbored a pooled sensitivity of 0.82(95% CI: 0.73, 0.89), specificity of 0.80(95% CI: 0.67, 0.88), AUC (area under the curve) of 0.88 (95% CI: 0.85–0.91) in discriminating patients with cancer from cancer-free controls. Additionally, the combined positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odd ratio (DOR) describing the discriminatory ability were 4.08 (95% CI: 2.45-6.8), 0.22 (95% CI: 0.14-0.35) and 18.48 (95% CI: 8.39-40.72) in the analysis. Furthermore, for non-small cell lung cancer (NSCLC), the pooled sensitivity, specificity and AUC of linc00312 were estimated to be 0.86(95% CI: 0.81, 0.90), 0.78(95% CI: 0.60, 0.89), and 0.89 (95% CI: 0.86–0.91). \nConclusions: Linc00312 might be indicative of greater tumor size, shorter survival and might be a potential diagnostic biomarker in solid tumors. Further studies are necessary to determine the value of this diagnostic biomarker in clinical management of patients with cancer.